European Molecular Biology Laboratory And Abnova (Taiwan) Corporation Announce Partnership Agreement For High-Throughput Monoclonal Antibody Production
10/19/2005 5:12:09 PM
EMBL, the leading European molecular biology research institute, has joined force with Abnova Corporation to set the precedent for high-throughput monoclonal antibody production. Abnova is a bio-tool company with extensive experience in industrial-scale production of recombinant proteins and antibodies. Under the partnership, EMBL's adjunctive technologies relating to automated platform and monoclonal antibody production developed in EMBL Monoclonal Core Facility at Monterotondo, Italy will augment Abnova's in-house capability and infrastructure. The partnership also provides the framework for the marketing collaboration between EMBL Enterprise Management (EMBLEM) and Abnova for the custom OEM monoclonal antibody business. A subsidiary of Abnova, Abnova GmbH is formed to consolidate and expand the company's custom service to meet the large-scale antibody needs of the academic and industrial communities worldwide.
comments powered by